Stem cell-derived Schwann cells
AssigneeMemorial Sloan Kettering Cancer Center
InventorsLorenz Studer, Faranak Fattahi
Life of this patent
Estimating the term…
Abstract
The presently disclosed subject matter provides for in vitro methods of inducing differentiation of stem cells into Schwann cell precursors and Schwann cells, and Schwann cell precursors and Schwann cells generated by such methods. The presently disclosed subject matter also provides for uses of such Schwann cell precursors and Schwann cells for regeneration of PNS and/or CNS, for prevention and/or repair of myelin damages, and/or for prevention and/or treatment of Schwann cell related disorders (e.g., peripheral neuropathy, e.g., Diabetic Peripheral Neuropathy).
Claims13
An in vitro method for inducing differentiation of SOX10-expressing neural crest lineage cells, comprising aggregating the SOX10-expressing neural crest lineage cells into 3D spheroids and concurrently contacting the 3D spheroids with at least one Wnt activator, at least one FGF activator, and at least one Schwann Cell (SC) differentiation inducer to produce a population of differentiated cells that express the Schwann cell precursor marker glial fibrillary acidic protein (GFAP);
- wherein the at least one Wnt activator lowers glycogen synthase kinase 3B (GSK3B) for activation of Wnt signaling;
- wherein the at least one FGF activator is selected from the group consisting of FGF1, FGF2, FGF4, FGF8, and mixtures thereof;
- wherein the at least one SC differentiation inducer comprises a neuregulin.
Dependencies are inferred from the claim text.